Agilon Health, Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2024. Agilon Health operates a "Total Care Model" designed to empower primary care physicians (PCPs) to manage the total healthcare needs of Medicare Advantage (MA) members through globally capitated arrangements. The company forms risk-bearing entities (RBEs) in local geographies that contract with payors and anchor physician groups. As of year-end 2024, the platform served approximately 526,500 MA members and 132,100 beneficiaries through CMS Accountable Care Organization (ACO) models across 30 geographies with 29 anchor physician groups.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 |
|---|---|---|
| Total Revenue | $6,060.5 | $4,316.4 |
| Medical Services Expense | $5,842.5 | $4,008.7 |
| Gross Profit | $4.8 | $69.7 |
| Medical Margin (Non-GAAP) | $205.2 | $298.7 |
| Net Loss | $(260.1) | $(262.8) |
| Adjusted EBITDA Loss (Non-GAAP) | $(154.2) | $(95.0) |
| Cash and Cash Equivalents | $188.2 | $107.6 |
| Marketable Securities | $211.7 | $380.8 |
| Long-Term Debt (Net) | $34.9 | $32.3 |
Note: Medical Margin is defined by the company as medical services revenue less medical services expense. Gross Profit is the most directly comparable GAAP measure.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 40% to $6.06 billion, driven primarily by a 38% increase in average membership (adding seven new geographies) and a 2% increase in per-member-per-month (PMPM) capitation rates.
- Margin Compression: Gross profit collapsed from $69.7 million in 2023 to $4.8 million in 2024. Medical margin decreased by $93.5 million (31%).
- Expense Drivers: Medical services expense rose 46% to $5.84 billion. This outpaced revenue growth due to a 6% increase in average medical services expense per member, attributed to elevated medical cost trends and unfavorable prior period reserve development.
- Discontinued Operations: Losses from discontinued operations (Hawaii and California divestitures) improved significantly, decreasing from $67.6 million in 2023 to $9.8 million in 2024.
- Stock Performance: The company's stock price declined significantly, with total shareholder return dropping from $100 in April 2021 to $8 as of December 31, 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Commentary: Management expects to continue incurring operating losses and generating negative cash flows from operations in the foreseeable future due to investments in business expansion. The company anticipates that medical margin will increase in absolute dollars as the platform matures, though new membership is typically dilutive to margin on a per-member basis.
Key Risks:
- Regulatory and Audit Risk: Significant exposure to CMS Risk-Adjustment Data Validation (RADV) audits, which can result in payment recoveries and penalties. The company faces ongoing scrutiny regarding coding accuracy and documentation.
- Legal Proceedings: The company is subject to consolidated securities class action litigation alleging fraud related to financial guidance, medical margin, and data management. Derivative lawsuits are also pending.
- Payor Concentration: Revenue is heavily concentrated among a limited number of key payors (e.g., Payor A at 21%, Payor B at 18%). Loss of these contracts would be material.
- Internal Controls: The company previously identified a material weakness regarding the completeness and accuracy of information produced by the entity (IPE) for medical claims and revenue. Management states this was remediated as of December 31, 2024, and the auditor issued an unqualified opinion on internal controls.
- Capital Requirements: The company may require additional capital to fund operations and growth, which could be difficult to obtain on favorable terms given current market conditions and the company's loss history.
Investor Verification Checklist
- Medical Cost Trends: Verify the sustainability of the 6% increase in medical services expense per member and the adequacy of current reserves for Incurred But Not Reported (IBNR) claims.
- Margin Trajectory: Assess the company's ability to reverse the sharp decline in medical margin and gross profit despite significant revenue growth.
- Legal Exposure: Monitor the status of the consolidated securities litigation and potential financial impact of settlements or judgments.
- Payor Contract Renewals: Review the terms and renewal status of contracts with top payors, given the high concentration risk.
- Cash Burn Rate: Evaluate the runway provided by current cash ($188.2M) and marketable securities ($211.7M) against the projected negative operating cash flow of $57.8M for 2024.